Sun et al. developed a DNA vaccine using a plasmid encoding calreticulin (CRT) and E7 protein and managed to evoke a potent CD8 T-cell response, which could ultimately lead to anti-tumour effects and survival [137]. Here, CD8A is linked to neoplasm.